RBC Capital Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $181
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) but lowers the price target from $182 to $181.
August 08, 2024 | 8:11 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital maintains an Outperform rating on Sarepta Therapeutics but lowers the price target from $182 to $181.
The Outperform rating suggests continued confidence in the stock's performance, but the slight reduction in the price target may indicate minor concerns or adjustments in valuation. Overall, the impact is neutral as the rating remains positive.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100